[Inhibition of angiogenesis with antisense ODN of VEGF].
OBJECTIVE
To investigate whether antisense oligodeoxynucletides(ODNs) of VEGF can become a kind of drugs for antitumor cancer treatment.


METHODS
With a tumor model on the cornea of the mouse the inhibition of angiogenesis and tumor growth by 5 ODNs with different modifications and sequences was determined.


RESULTS
ODNs with partial phosphorothioate modification, or with hairpin structure could effectively inhibit tumor-induced angiogenesis, but the linear ODN could not. The use of 2 ODNs at different sites gave the best results.


CONCLUSIONS
VEGF antisense ODNs can hopefully become new drug with antitumor and antiangiogenesis activities.
Dong
F
F
State Key Lab of Molecular Biology, Shanghai Institute of Biochemistry, Academia Sinica.
Jin
Y
Y
D000818:Animals; D003316:Corneal Diseases / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000627:therapeutic use*; D005134:Eye Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D008222:Lymphokines / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D012509:Sarcoma / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D016376:Oligonucleotides, Antisense; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors